Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04409223 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | terminated | Phase 3 | 185 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT00812240 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | terminated | Phase 3 | 335 | AB ScienceINDUSTRY | 3 | Feb 1, 2023 | clinicaltrials |
| NCT00324987 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor(S0502) | terminated | Phase 3 | 12 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2017 | clinicaltrials |
| NCT00009906 | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | terminated | Phase 3 | 748 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00751036 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg(MACS0375) | terminated | Phase 3 | 94 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 26, 2014 | clinicaltrials |
| NCT01031628 | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | terminated | Phase 3 | 5 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00688766 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | terminated | Phase 3 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00956072 | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | terminated | Phase 3 | 12 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00372567 | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | terminated | Phase 3 | 69 | PfizerINDUSTRY | 7 | Mar 17, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Feb 9, 2024source: clinicaltrials